---
id: "action-cross-border-trials"
type: "action-item"
source_timestamps: ["§ 5. Continue to drive global collaborations."]
tags: ["clinical-trials", "global-strategy"]
related: ["entity-msk", "quote-disease-borders"]
action: "Establish international clinical trial partnerships to harmonize regulations and boost patient enrollment."
outcome: "Reduced operational costs, faster trial completion, and optimized global drug market access."
speakers: ["Anaeze C. Offodile II", "Kushal T. Kadakia", "Yashodhara Dash", "Whitney Snider", "Joseph C. Wu", "Selwyn M. Vickers"]
sources: ["tail2"]
sourceVaultSlug: "hbr-seg-tail2"
originDay: 2
articleStem: "hbr-tail-131-medical-drug-discovery"
sourceUrl: "https://hbr.org/2026/04/u-s-medical-centers-need-a-new-model-for-drug-discovery-and-development"
sourceTitle: "U.S. Medical Centers Need a New Model for Drug Discovery and Development"
---
# Foster Cross-Border Clinical Collaborations

**Action:** Engage in **multi-stakeholder international partnerships** (e.g., the **U.S.–Australia Alliance**) to **boost patient enrollment, avoid duplicative testing, and support regulatory harmonization** between the FDA and global agencies.

**Mechanism / example:** [[entity-msk]]'s membership in the U.S.–Australia Alliance for Cancer Research and Treatment (Pillar 5 of [[framework-amc-innovation-acceleration]]); rationale in [[quote-disease-borders]].

**Outcome:** reduced operational costs, faster trial completion, and optimized global drug-market access. **Enrichment note:** cross-border collaboration remains constrained by **data-governance and ethics differences**.


## Related across articles
- [[concept-ecosystem-acceleration]]